Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sagimet Biosciences Inc.NASDAQ: SGMT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $7M fell 54.4% year over year, behind the -36.7% change in trailing-twelve-month research & development. Sequentially, it rose 3.9% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -54.4% toward the trailing-twelve-month pace of -36.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 39.05M USD
- Year-over-year change
- +1.6%
- 4-year CAGR
- +19.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.05M | +1.6% |
| FY2024 | 2024-12-31 | 38.44M | +94.4% |
| FY2023 | 2023-12-31 | 19.78M | -20.6% |
| FY2022 | 2022-12-31 | 24.92M | +28.8% |
| FY2021 | 2021-12-31 | 19.34M | — |
Research & Development vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 research & development of $30.71M is the 10th highest of the 11 companies compared; the peer median is $90.17M.
- Its year-over-year change of -36.7% is the 10th highest of 11, against a peer median of +3.5%.
- Over three fiscal years its annual growth of +16.2% compares with a peer median of +4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.68B | +22061.7% | +5.1% | — | |
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $143.25M | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $127.75M | -3.1% | +30.4% | 350.1% | |
| LTM Mar 2026 | $98.25M | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $64.86M | +10.1% | -2.5% | 91.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M | +48.2% | +21.1% | — |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $30.71M | -36.7% | +16.2% | — |
| LTM Mar 2026 | $19.19M | -29.2% | -8.6% | — | |
| Peer median (excluding SGMT) | $90.17M | +3.5% | +4.1% | 320.5% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| Selling, General & Admin | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| Operating Expenses | 23.72M | 31.06M | 32.74M | 54.45M | 56.89M |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| EBITDA | (24.44M) | (30.37M) | (27.88M) | (45.57M) | (51.04M) |
| EBITDA Margin | — | — | -1393.8% | — | — |
| Operating Income | (23.72M) | (31.06M) | (30.74M) | (54.45M) | (56.89M) |
| Operating Margin | — | — | -1537.0% | — | — |
| Interest Income | 26K | 553K | 2.86M | 8.89M | 5.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (723K) | 556K | 2.86M | 8.89M | 5.85M |
| Income Before Tax | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Pre-Tax Margin | — | — | -1393.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Net Margin | — | — | -1393.8% | — | — |
| EPS (Basic) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| EPS (Diluted) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| Weighted Avg Shares | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
| Weighted Avg Shares (Diluted) | 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.